CORT
NASDAQCorcept Therapeutics Incorporated
Price$116.29+2.08 (+1.82%)
01:30 PM04:15 PM
News · 26 weeks89+15%
2026-03-152026-09-06
Mix3890d
- Insider28(74%)
- SEC Filings3(8%)
- Other2(5%)
- Earnings2(5%)
- Analyst2(5%)
- Leadership1(3%)
Latest news
25 items- PRBloom Energy, Illumina, and Everpure Set to Join S&P 500; Others to Join S&P 100, S&P MidCap 400, and S&P SmallCap 600NEW YORK, Sept. 4, 2026 /PRNewswire/ -- S&P Dow Jones Indices will make the following changes to the S&P 500, S&P 100, S&P MidCap 400, and S&P SmallCap 600 indices effective prior to the open of trading on Monday, September 21, 2026, to coincide with the quarterly rebalance. The changes ensure that each index is more representative of its market capitalization range. The companies being removed from the S&P SmallCap 600 are no longer representative of the small-cap market space. Following is a summary of the changes that will take place prior to the open of trading on the effective date:Effective Date Index Name Action Company Name Ticker GICS Sector Sept 21, 2026 S&P 100AdditionDell Techno
- INSIDERChief Development Officer Guyer William was granted 328 shares, increasing direct ownership by 8% to 4,313 units (SEC Form 4)4 - CORCEPT THERAPEUTICS INC (0001088856) (Issuer)
- INSIDEROfficer Maduck Sean covered exercise/tax liability with 117 shares, exercised 25,000 shares at a strike of $8.27, sold $2,860,737 worth of shares (25,000 units at $114.43) as part of a pre-agreed trading plan and was granted 300 shares, increasing direct ownership by 2% to 9,938 units (SEC Form 4) (for withholding tax)4 - CORCEPT THERAPEUTICS INC (0001088856) (Issuer)
- INSIDERChief Financial Officer Mokari Atabak covered exercise/tax liability with 102 shares and was granted 276 shares, increasing direct ownership by 1% to 16,304 units (SEC Form 4) (withholding obligation)4 - CORCEPT THERAPEUTICS INC (0001088856) (Issuer)
- INSIDERChief Business Officer Robb Gary Charles was granted 328 shares and covered exercise/tax liability with 91 shares, increasing direct ownership by 2% to 13,663 units (SEC Form 4) to satisfy withholding obligation4 - CORCEPT THERAPEUTICS INC (0001088856) (Issuer)
- INSIDERPresident, Oncology Vieira Roberto Wandenkolk was granted 276 shares, covered exercise/tax liability with 102 shares, exercised 58,333 shares at a strike of $21.63 and sold $6,460,766 worth of shares (58,333 units at $110.76) as part of a pre-agreed trading plan, increasing direct ownership by 4% to 4,242 units (SEC Form 4) to cover withholding tax4 - CORCEPT THERAPEUTICS INC (0001088856) (Issuer)
- INSIDEROfficer Lyon Joseph Douglas was granted 260 shares and covered exercise/tax liability with 72 shares, increasing direct ownership by 3% to 5,683 units (SEC Form 4) to cover taxes4 - CORCEPT THERAPEUTICS INC (0001088856) (Issuer)
- INSIDERNew insider Vieira Roberto Wandenkolk claimed ownership of 4,068 shares (SEC Form 3)3 - CORCEPT THERAPEUTICS INC (0001088856) (Issuer)
- INSIDERDirector Park Kimberly exercised 30,000 shares at a strike of $13.49, covered exercise/tax liability with 3,315 shares and sold $3,270,169 worth of shares (26,685 units at $122.55) (SEC Form 4)4 - CORCEPT THERAPEUTICS INC (0001088856) (Issuer)
- INSIDEROfficer Maduck Sean exercised 30,955 shares at a strike of $11.35 and sold $3,887,320 worth of shares (30,955 units at $125.58) as part of a pre-agreed trading plan (SEC Form 4)4 - CORCEPT THERAPEUTICS INC (0001088856) (Issuer)
- INSIDERDirector Mahoney David L sold $12,251,411 worth of shares (103,606 units at $118.25) as part of a pre-agreed trading plan (SEC Form 4)4 - CORCEPT THERAPEUTICS INC (0001088856) (Issuer)
- INSIDERDirector Wilson James N sold $1,114,261 worth of shares (10,000 units at $111.43) as part of a pre-agreed trading plan (SEC Form 4)4 - CORCEPT THERAPEUTICS INC (0001088856) (Issuer)
- INSIDERChief Business Officer Robb Gary Charles sold $1,162,572 worth of shares (10,000 units at $116.26) and gifted 125 shares, decreasing direct ownership by 0.92% to 13,426 units (SEC Form 4)4 - CORCEPT THERAPEUTICS INC (0001088856) (Issuer)
- INSIDEROfficer Maduck Sean exercised 3,664 shares at a strike of $8.27 and sold $419,491 worth of shares (3,664 units at $114.49) as part of a pre-agreed trading plan (SEC Form 4)4 - CORCEPT THERAPEUTICS INC (0001088856) (Issuer)
- ANALYSTTruist resumed coverage on Corcept Therapeutics with a new price targetTruist resumed coverage of Corcept Therapeutics with a rating of Buy and set a new price target of $164.00
- INSIDERChief Business Officer Robb Gary Charles gifted 11,530 shares and received a gift of 6,000 shares, decreasing direct ownership by 46% to 13,551 units (SEC Form 4)4 - CORCEPT THERAPEUTICS INC (0001088856) (Issuer)
- SECAmendment: SEC Form SCHEDULE 13G/A filed by Corcept Therapeutics IncorporatedSCHEDULE 13G/A - CORCEPT THERAPEUTICS INC (0001088856) (Subject)
- INSIDEROfficer Maduck Sean exercised 1,031 shares at a strike of $8.27 and sold $118,068 worth of shares (1,031 units at $114.52) as part of a pre-agreed trading plan (SEC Form 4)4 - CORCEPT THERAPEUTICS INC (0001088856) (Issuer)
- INSIDERChief Development Officer Guyer William exercised 16,300 shares at a strike of $21.65 and sold $1,848,890 worth of shares (16,300 units at $113.43) as part of a pre-agreed trading plan (SEC Form 4)4 - CORCEPT THERAPEUTICS INC (0001088856) (Issuer)
- INSIDERChief Development Officer Guyer William exercised 3,700 shares at a strike of $21.65 and sold $418,562 worth of shares (3,700 units at $113.12) as part of a pre-agreed trading plan (SEC Form 4)4 - CORCEPT THERAPEUTICS INC (0001088856) (Issuer)
- INSIDEROfficer Maduck Sean exercised 20,305 shares at a strike of $8.27 and sold $2,329,075 worth of shares (20,305 units at $114.70) as part of a pre-agreed trading plan (SEC Form 4)4 - CORCEPT THERAPEUTICS INC (0001088856) (Issuer)
- INSIDEROfficer Lyon Joseph Douglas sold $175,806 worth of shares (1,540 units at $114.16), decreasing direct ownership by 22% to 5,495 units (SEC Form 4)4 - CORCEPT THERAPEUTICS INC (0001088856) (Issuer)
- INSIDERChief Financial Officer Mokari Atabak sold $9,177,109 worth of shares (80,000 units at $114.71) as part of a pre-agreed trading plan and exercised 80,000 shares at a strike of $23.06 (SEC Form 4)4 - CORCEPT THERAPEUTICS INC (0001088856) (Issuer)
- SECSEC Form 10-Q filed by Corcept Therapeutics Incorporated10-Q - CORCEPT THERAPEUTICS INC (0001088856) (Filer)
- SECCorcept Therapeutics Incorporated filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits8-K - CORCEPT THERAPEUTICS INC (0001088856) (Filer)
CORT FAQ
7 questionsWhat does Corcept Therapeutics Incorporated do?
Corcept Therapeutics Incorporated discovers, develops, and commercializes drugs for the treatment of severe metabolic, oncologic, and psychiatric disorders in the United States. The company offers Korlym (mifepristone) tablets as a once-daily oral medication for the treatment of hyperglycemia secondary to hypercortisolism in adult patients with endogenous Cushing's syndrome, who have type 2 diabetes mellitus or glucose intolerance, and have failed surgery or are not candidates for surgery. It is developing relacorilant to treat patients with Cushing's syndrome; and nab-paclitaxel in...Where does CORT stock trade?
Corcept Therapeutics Incorporated (CORT) is listed on NASDAQ.What sector and industry is CORT in?
Corcept Therapeutics Incorporated operates in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry.When did Corcept Therapeutics Incorporated go public?
Corcept Therapeutics Incorporated (CORT) completed its IPO in 2004.What are analysts saying about CORT?
Corcept Therapeutics Incorporated has had 8 recent analyst actions on file. The most recent action was from Truist: Buy on 2026-08-18. Recent price targets range from $3000.00 to $3800.00.What companies are similar to CORT?
Notable peers in the same industry include LLY (Eli Lilly and Company), JNJ (Johnson & Johnson), ABBV (AbbVie Inc.), MRK (Merck & Company Inc.), NVS (Novartis AG). Compare CORT side-by-side with any of them on Quantisnow.How can I track CORT on Quantisnow?
Quantisnow aggregates Corcept Therapeutics Incorporated's SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow CORT to receive live email and push alerts on every new disclosure.